Benzinga | Mar 30, 2021 06:03AM EDT

Akebia Submits New Drug Application To FDA For Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis And Not On Dialysis

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.